Allosteric Hemoglobin Modulators for Sickle Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics are inadequate for treating disorders mediated by abnormal hemoglobin, such as sickle cell disease, which results from the polymerization of sickle hemoglobin (HbS) leading to rigid red blood cells and oxygen delivery issues.
Innovation Solution
Development of compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically increasing oxygen affinity of hemoglobin S, formulated as compounds of certain structural formulas and their pharmaceutically acceptable salts or N-oxides, which can be administered to treat disorders associated with oxygen deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to treat sickle cell disease by addressing HbS polymerization, then the oxygen delivery issues can be improved, but no effective therapeutics currently exist to resolve the underlying polymerization problem
Solution Approach 1:
The patent applies parameter changes by modifying the oxygen affinity parameter of hemoglobin S through allosteric modulation. The compounds bind to hemoglobin and alter its conformational equilibrium, shifting the oxygen dissociation curve to increase oxygen affinity. This parameter change prevents HbS polymerization by stabilizing the R-state (relaxed, high-affinity state), thereby treating sickle cell disease without requiring genetic modification or complex delivery systems.
2Stability of the object's composition
If HbS polymerization is prevented through allosteric modulation, then red blood cell rigidity and sickle shape formation can be reduced, but the structural complexity of the compound required to achieve specific binding increases
Solution Approach 1:
The patent employs an intermediary approach by introducing small molecule compounds that act as mediators between the therapeutic goal and the molecular target. These compounds serve as intermediaries that bind to allosteric sites on hemoglobin, translating the therapeutic intent of preventing polymerization into actual molecular conformational changes. The intermediary compounds have defined structural features (specific ring systems, substituent patterns) that enable selective binding while maintaining reasonable synthetic accessibility.
Solution Approach 2:
The patent applies local quality by designing compounds with specific functional groups and substituent patterns at particular positions on the molecular scaffold. The structures feature localized aromatic rings (phenyl, pyridyl, pyrimidinyl groups) with specific substituents (halogens, alkyl groups, nitro groups) at defined positions, creating localized interaction zones that target specific regions of the hemoglobin binding site. This localized functional distribution achieves high binding specificity without requiring complete molecular complexity throughout the entire structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase oxygen affinity of hemoglobin S, addressing the oxygen delivery issues in sickle cell anemia and potentially treating other conditions by enhancing tissue and cellular oxygenation.
Implementation Method 1
compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin
Implementation Method 2
Hemoglobin binds and releases oxygen through conformational changes
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.